124 related articles for article (PubMed ID: 16451063)
1. 3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
Tedesco R; Shaw AN; Bambal R; Chai D; Concha NO; Darcy MG; Dhanak D; Fitch DM; Gates A; Gerhardt WG; Halegoua DL; Han C; Hofmann GA; Johnston VK; Kaura AC; Liu N; Keenan RM; Lin-Goerke J; Sarisky RT; Wiggall KJ; Zimmerman MN; Duffy KJ
J Med Chem; 2006 Feb; 49(3):971-83. PubMed ID: 16451063
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.
Randolph JT; Flentge CA; Huang PP; Hutchinson DK; Klein LL; Lim HB; Mondal R; Reisch T; Montgomery DA; Jiang WW; Masse SV; Hernandez LE; Henry RF; Liu Y; Koev G; Kati WM; Stewart KD; Beno DW; Molla A; Kempf DJ
J Med Chem; 2009 May; 52(10):3174-83. PubMed ID: 19402666
[TBL] [Abstract][Full Text] [Related]
3. Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate.
Slater MJ; Amphlett EM; Andrews DM; Bravi G; Burton G; Cheasty AG; Corfield JA; Ellis MR; Fenwick RH; Fernandes S; Guidetti R; Haigh D; Hartley CD; Howes PD; Jackson DL; Jarvest RL; Lovegrove VL; Medhurst KJ; Parry NR; Price H; Shah P; Singh OM; Stocker R; Thommes P; Wilkinson C; Wonacott A
J Med Chem; 2007 Mar; 50(5):897-900. PubMed ID: 17269759
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of heteroaryl 3-(1,1-dioxo-2H-(1,2,4)-benzothiadizin-3-yl)-4-hydroxy-2(1H)-quinolinone derivatives as hepatitis C virus NS5B polymerase inhibitors.
Tedesco R; Chai D; Darcy MG; Dhanak D; Fitch DM; Gates A; Johnston VK; Keenan RM; Lin-Goerke J; Sarisky RT; Shaw AN; Valko KL; Wiggall KJ; Zimmerman MN; Duffy KJ
Bioorg Med Chem Lett; 2009 Aug; 19(15):4354-8. PubMed ID: 19505821
[TBL] [Abstract][Full Text] [Related]
5. A highly efficient, asymmetric synthesis of benzothiadiazine-substituted tetramic acids: potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
Fitch DM; Evans KA; Chai D; Duffy KJ
Org Lett; 2005 Nov; 7(24):5521-4. PubMed ID: 16288546
[TBL] [Abstract][Full Text] [Related]
6. HCV NS5B polymerase inhibitors 3: Synthesis and in vitro activity of 3-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-4-hydroxy-2H-quinolizin-2-one derivatives.
Wang G; Zhang L; Wu X; Das D; Ruhrmund D; Hooi L; Misialek S; Ravi Rajagopalan PT; Buckman BO; Kossen K; Seiwert SD; Beigelman L
Bioorg Med Chem Lett; 2009 Aug; 19(15):4484-7. PubMed ID: 19497737
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.
Wagner R; Larson DP; Beno DW; Bosse TD; Darbyshire JF; Gao Y; Gates BD; He W; Henry RF; Hernandez LE; Hutchinson DK; Jiang WW; Kati WM; Klein LL; Koev G; Kohlbrenner W; Krueger AC; Liu J; Liu Y; Long MA; Maring CJ; Masse SV; Middleton T; Montgomery DA; Pratt JK; Stuart P; Molla A; Kempf DJ
J Med Chem; 2009 Mar; 52(6):1659-69. PubMed ID: 19226162
[TBL] [Abstract][Full Text] [Related]
8. The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine.
Smith DB; Kalayanov G; Sund C; Winqvist A; Pinho P; Maltseva T; Morisson V; Leveque V; Rajyaguru S; Le Pogam S; Najera I; Benkestock K; Zhou XX; Maag H; Cammack N; Martin JA; Swallow S; Johansson NG; Klumpp K; Smith M
J Med Chem; 2009 Jan; 52(1):219-23. PubMed ID: 19055482
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel HCV RNA-dependent RNA polymerase inhibitors using pharmacophore-guided virtual screening.
Kim J; Kim KS; Kim DE; Chong Y
Chem Biol Drug Des; 2008 Dec; 72(6):585-91. PubMed ID: 19090925
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel tricyclic indole derived inhibitors of HCV NS5B RNA dependent RNA polymerase.
Venkatraman S; Velazquez F; Gavalas S; Wu W; Chen KX; Nair AG; Bennett F; Huang Y; Pinto P; Jiang Y; Selyutin O; Vibulbhan B; Zeng Q; Lesburg C; Duca J; Huang HC; Agrawal S; Jiang CK; Ferrari E; Li C; Kozlowski J; Rosenblum S; Shih NY; Njoroge FG
Bioorg Med Chem; 2013 Apr; 21(7):2007-17. PubMed ID: 23434368
[TBL] [Abstract][Full Text] [Related]
11. Simple but highly effective three-dimensional chemical-feature-based pharmacophore model for diketo acid derivatives as hepatitis C virus RNA-dependent RNA polymerase inhibitors.
Di Santo R; Fermeglia M; Ferrone M; Paneni MS; Costi R; Artico M; Roux A; Gabriele M; Tardif KD; Siddiqui A; Pricl S
J Med Chem; 2005 Oct; 48(20):6304-14. PubMed ID: 16190757
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication.
Clark JL; Hollecker L; Mason JC; Stuyver LJ; Tharnish PM; Lostia S; McBrayer TR; Schinazi RF; Watanabe KA; Otto MJ; Furman PA; Stec WJ; Patterson SE; Pankiewicz KW
J Med Chem; 2005 Aug; 48(17):5504-8. PubMed ID: 16107149
[TBL] [Abstract][Full Text] [Related]
13. HCV NS5B polymerase inhibitors 1: Synthesis and in vitro activity of 2-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-1-hydroxynaphthalene derivatives.
Wang G; He Y; Sun J; Das D; Hu M; Huang J; Ruhrmund D; Hooi L; Misialek S; Ravi Rajagopalan PT; Stoycheva A; Buckman BO; Kossen K; Seiwert SD; Beigelman L
Bioorg Med Chem Lett; 2009 Aug; 19(15):4476-9. PubMed ID: 19502055
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.
Eldrup AB; Prhavc M; Brooks J; Bhat B; Prakash TP; Song Q; Bera S; Bhat N; Dande P; Cook PD; Bennett CF; Carroll SS; Ball RG; Bosserman M; Burlein C; Colwell LF; Fay JF; Flores OA; Getty K; LaFemina RL; Leone J; MacCoss M; McMasters DR; Tomassini JE; Von Langen D; Wolanski B; Olsen DB
J Med Chem; 2004 Oct; 47(21):5284-97. PubMed ID: 15456273
[TBL] [Abstract][Full Text] [Related]
15. HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives.
Wang G; Lei H; Wang X; Das D; Hong J; Mackinnon CH; Coulter TS; Montalbetti CA; Mears R; Gai X; Bailey SE; Ruhrmund D; Hooi L; Misialek S; Rajagopalan PT; Cheng RK; Barker JJ; Felicetti B; Schönfeld DL; Stoycheva A; Buckman BO; Kossen K; Seiwert SD; Beigelman L
Bioorg Med Chem Lett; 2009 Aug; 19(15):4480-3. PubMed ID: 19500983
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.
Lu L; Dekhtyar T; Masse S; Pithawalla R; Krishnan P; He W; Ng T; Koev G; Stewart K; Larson D; Bosse T; Wagner R; Pilot-Matias T; Mo H; Molla A
Antiviral Res; 2007 Oct; 76(1):93-7. PubMed ID: 17561278
[TBL] [Abstract][Full Text] [Related]
17. A homogeneous, solid-phase assay for hepatitis C virus RNA-dependent RNA polymerase.
Wang YK; Rigat KL; Roberts SB; Gao M
Anal Biochem; 2006 Dec; 359(1):106-11. PubMed ID: 17054898
[TBL] [Abstract][Full Text] [Related]
18. An efficient, asymmetric solid-phase synthesis of benzothiadiazine-substituted tetramic acids: potent inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
Evans KA; Chai D; Graybill TL; Burton G; Sarisky RT; Lin-Goerke J; Johnston VK; Rivero RA
Bioorg Med Chem Lett; 2006 Apr; 16(8):2205-8. PubMed ID: 16455253
[TBL] [Abstract][Full Text] [Related]
19. Identification of small molecule inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture.
Burton G; Ku TW; Carr TJ; Kiesow T; Sarisky RT; Lin-Goerke J; Baker A; Earnshaw DL; Hofmann GA; Keenan RM; Dhanak D
Bioorg Med Chem Lett; 2005 Mar; 15(6):1553-6. PubMed ID: 15745795
[TBL] [Abstract][Full Text] [Related]
20. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.
Venkatraman S; Bogen SL; Arasappan A; Bennett F; Chen K; Jao E; Liu YT; Lovey R; Hendrata S; Huang Y; Pan W; Parekh T; Pinto P; Popov V; Pike R; Ruan S; Santhanam B; Vibulbhan B; Wu W; Yang W; Kong J; Liang X; Wong J; Liu R; Butkiewicz N; Chase R; Hart A; Agrawal S; Ingravallo P; Pichardo J; Kong R; Baroudy B; Malcolm B; Guo Z; Prongay A; Madison V; Broske L; Cui X; Cheng KC; Hsieh Y; Brisson JM; Prelusky D; Korfmacher W; White R; Bogdanowich-Knipp S; Pavlovsky A; Bradley P; Saksena AK; Ganguly A; Piwinski J; Girijavallabhan V; Njoroge FG
J Med Chem; 2006 Oct; 49(20):6074-86. PubMed ID: 17004721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
